Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis - Top-Institutions - MDSpire

Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis

  • By

  • Rong Chen

  • Zhenyu Huo

  • Xuelin Yang

  • Xiaohu Cui

  • Xin Liu

  • Fang Wang

  • February 19, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Oncology
    • Immunology
    • Infectious Diseases

  • #2

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Oncology
    • Transplant Medicine

  • #3

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Oncology
    • Infectious Diseases
    • Immunology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Immunotherapy
    • Molecular Pathology

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Oncology
    • Infectious Diseases
    • Transplant Medicine

Original Source(s)

Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis

  • by Rong Chen, Zhenyu Huo, Xuelin Yang, Xiaohu Cui, Xin Liu, Fang Wang

  • February 19, 2026

Related Content

Hemozoin-induced immunomodulation and prostate carcinogenesis: mechanisms and implications

A Pharmacologic Off-Switch for Split CARs

Study describes a venetoclax-regulated off-switch CAR system with dose-dependent control of receptor assembly in vitro and in vivo

  • March 3, 2026

  • 2 min
Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.